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Table 1
Cytoreductive
Response n (%)
No Cytoreductive
Response n (%)
n¼16 8 (50) 8 (50)
Alive at Day 100 5 (31) 6 (38)
Alive, Day 100 Not Reached 1 (25) 1 (25)
Alive, in remission 5 (31) 3 (19)
Alive, relapsed 0 (0) 1 (6)
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plerixafor as part of their mobilization regimen at CCHMC
between January 2011 and September 2013 was conducted.
All patients receiving at least one dose were included. Data
on the number of plerixafor doses administered, cells
collected, and adverse events related to plerixafor were
collected.
Results: Eleven patients received plerixafor during the
designated time period; 9/11 patients (81.8%) had relapsed
malignancies and 2/11 patients (18.2%) required 3 and 4
autologous stem cell transplants for brain tumors. The me-
dian age of patients receiving plerixafor was 6 years (range 3-
15 years). All patients were given 0.24 mg/kg of plerixafor
and the median number of plerixafor doses received was 3
(range 1-4 doses). Collection target was 1x106 of CD34+cells/
kg for each transplant. An adequate number of CD34+ cells
were obtained in 9 of 11 patients (81.8%). The median
number of CD34+ cells collected for patients who reached
collection goal was 5.7x 106/kg (range 1.3-12.4 x 106/kg). No
acute adverse events were noted to be attributable to pler-
ixafor administration.
Conclusion: Our ﬁndings suggest that plerixafor use in
children is safe and efﬁcacious for the mobilization of PBSCs
in children with relapsed malignancies or requiring stem
cells for multiple transplants.462
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Outcomes in patients with relapsed/refractory acute myeloid
leukemia or advancedmyelodysplastic syndromewith active
disease at the time of allogeneic hematopoietic stem cell
transplant (HSCT) are generally poor. Published data indicate
the purine analog clofarabine can be used for cytoreduction
in patients with active disease as a “bridge” to HSCT when
followed by a standard conditioning regimen.
At Weill Cornell Medical Center (WC) clofarabine has been
used in refractory patients as a bridge to HSCT since 2011.
While published studies transplanted patients at cytopenic
nadir following clofarabine therapy, WC transplanted pa-
tients without regard to cytoreductive response.
The purpose of this study was to retrospectively examine
survival following clofarabine therapy and to determine if
cytoreduction affects outcomes. Secondaryoutcomes included
cytoreduction (deﬁned as post-treatment cellularity<20% and
blasts <10%), relapse after transplant, and non-hematologic
toxicity.
The study included adult patients who received clofarabine
30 mg/m2/day IV x 5 days prior to HSCT between November
2011 and June 2013. Twenty-one patients received a clofar-
abine bridge; 18 (86%) proceeded to HCST. The three who did
not were septic at the scheduled time of transplant. Two
patients refused a day 14 bone marrow and were not eval-
uated for response. Both died post-transplant.
Of the evaluable 16 patients, 8 (50%) are alive and in remis-
sion at a median of 3 months (range 2-10). One is alive, but
relapsed. Overall, 5 patients (31%) relapsed. Of the 7 patients
who died after transplant, median overall survival was 94days (range 5-188). Causes of death included relapse, sepsis,
and engraftment failure.
Eight (50%) patients achieved the pre-deﬁned cytoreductive
response. Five are alive and in remission at a median of
5 months (range 3-10). See table 1.
Based on preliminary analysis, cytoreduction with a clofar-
abine bridge appears to positively affect outcomes of re-
fractory patients who proceed to HSCT.463
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Cyclophosphamide is a chemotherapeutic agent that may be
included in stem cell transplant preparative regimens.
Cyclophosphamide is a pro-drug that is converted to cyto-
toxic metabolites via multiple pathways of the cytochrome
P-450 enzyme system. The triazole antifungal agents may be
prescribed as fungal prophylaxis for stem cell transplant
patients. The triazole antifungals are inhibitors of some cy-
tochrome P-450 pathways that are utilized for cyclophos-
phamide conversion. Due to this drug interaction, some
transplant centers will substitute an alternate agent instead
of a triazole antifungal during cyclophosphamide therapy.
Adult data has demonstrated that there is no difference in
the AUC of the phosphoramide metabolite when given with
ﬂuconazole. The goal of this review is to examine if anti-
fungal drug interactions inﬂuence stem cell transplant sur-
vival or disease relapse. This is a single center, retrospective
review of 5 years of transplant outcomes for pediatric and
young adult patients diagnosed with a hematologic malig-
nancy that underwent hematopoietic stem cell transplant
and received cyclophosphamide as part of the transplant
preparative regimen. Outcomes measured were survival,
relapse or progressive disease and non-relapse mortality.
The medical charts of 25 patients with diagnoses of AML,
ALL, MDS and Lymphoma were reviewed. Outcomes were
stratiﬁed for voriconazole, ﬂuconazole and non-azole anti-
fungal patients. Survival results were 50% for voriconazole,
64% for ﬂuconazole and 33% for non-azole therapies. Relapse
or progressive disease rates were 16% for voriconazole, 18%
for ﬂuconazole and 33% for non-azole therapies. Non-relapse
mortality was 33% for voriconazole, 18% for ﬂuconazole and
33% for non-azole therapies. For azole versus non-azole
therapy relapse rates were 17% versus 33% respectively. In a
small cohort of pediatric and young adult patients, the
cytochrome P-450 interaction of azole antifungals and
cyclophosphamide does not appear to inﬂuence transplant
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ranted to examine this clinical question.TRANSPLANT NURSING ADMINISTRATION
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Improving Contact Precautions Compliance on Bone
Marrow Transplant ICU
Wendy Madden, Kathleen Carisch, Susanna Howell,
Jeanne Dockery. UAB, Birmingham, Alabama
Topic Signiﬁcance & Study Purpose/Background/
Rationale: Infections caused by multi-drug resistant organ-
isms (MDRO) have become increasingly prevalent in hospi-
tals over the last decade. More than 70% bacteria that cause
hospital-acquired infections are resistant to at least one drug
commonly used to treat these infections. Contact precautions
are important in preventing the spread of MDROs; however,
compliance in intensive care units (ICU) is known to be low.
Contact precautions compliance consists of hand hygiene
before entering patient room and upon exiting patient
room as well as utilizing gloves and gowns. Purpose: To
assess if contact precaution compliance improves among
Bone Marrow Transplant (BMT) ICU staff after providing
education.
Methods, Intervention, & Analysis: Physicians and nursing
staff completed a questionnaire assessing contact precaution
knowledge prior to an oral educational offering. Contact
precautions compliance audits utilizing the CDC MDRO form
were performed three months using 30 observations per
shift each month on a University hospital 16-bed BMT ICU.
This tool evaluated compliance with hand washing on room
entry and exit as well as gowning and gloving while in pa-
tient room. Staff were considered either compliant or non-
compliant with the contact precautions as a whole.
Findings & Interpretation: 70% of nursing staff and physi-
cians completed assessment questionnaires with a mean
score of 93.3%. Compliance with contact precautions was 14%
at baseline, 36.6% ﬁrst month, 61.7% second month, and
88.3% the third month. Stafﬁng for acuity was also moni-
tored. As acuity went down with improved stafﬁng, contact
precautions compliance went up.
Discussion & Implications: Contact precautions compliance
gradually improved during the study as nurse and physicians
became aware of audits - possibly a “Hawthorne Effect.”
Compliance slowly improved while acuity was high; how-
ever, signiﬁcant improvement was noted as acuity dropped.
Improved contact precautions compliance was not believedto be education related. Additional studies are needed to
evaluate the effect patient acuity and stafﬁng have on contact
precautions compliance.
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Empowered Bedside Bone Marrow Transplant Nurses:
The Key to Patient Satisfaction
Wendy Madden, Jeanne Dockery, Kirsten Larsen, Dana Oldham
. UAB, Birmingham, Alabama
Topic Signiﬁcance & Study Purpose/Background/
Rationale: A patient’s perception of his or her hospital stay
is directly impacted by the nursing care he or she receives.
With value-based purchasing on the horizon, the Centers for
Medicare and Medicaid will use patient satisfaction scores to
determine reimbursement. Psychological empowerment is a
perception that one has control of one’s work environment
with one’s values aligned with the organization. Structural
empowerment is the ability for the organization to offer
access to information, resources, support, and work oppor-
tunity. Psychological and structural nursing empowerment
directly impact patient satisfaction, reimbursement, and
organizational commitment.
Methods, Intervention, & Analysis: This study looked at
retrospective cross-sectional data of nursing empowerment
and patient satisfaction at a tertiary hospital 16 bed Bone
Marrow Transplant Inpatient Unit. The data collection review
was from October 2012 to October 2013.
Findings & Interpretation: The mean Press Ganey patient
satisfaction score for bone marrow transplant nursing was
95.5%. Average nursing experience was 8 years 10 months
with 98% staff retention. More than 75% of staff were
engaged in unit based committees that were nurse driven
including the Interdisciplinary Shared Governance Congress,
Research Committee, Education Committee, and Evidenced-
Based Practice Journal Club. 62% of staff were engaged in
hospital based committees and participated in providing
hospital CEU educational offerings. Nursing abstracts and
presentations were accepted to local, state, regional, na-
tional, and international conferences.
Discussion & Implications: Empowered nurses are more
autonomous in overcoming barriers to patient centered care;
and because they focus on service delivery, they partner with
the patient to enhance care delivery. Nursing empowerment
is directly related to patient satisfaction as well as organi-
zational commitment. Since patient satisfaction is being tied
to reimbursement, the engaged and empowered nurse ap-
pears to be the key. It is important to establish a unit culture
that empowers nursing staff.
